Fingolimod: un nuevo enfoque en el tratamiento de la esclerosis múltiple

Compston, 2002, Multiple sclerosis, Lancet, 359, 1221, 10.1016/S0140-6736(02)08220-X Rosati, 2001, The prevalence of multiple sclerosis in the world: an update, Neurol Sci, 22, 117, 10.1007/s100720170011 Noseworthy, 2000, Multiple sclerosis, N Engl J Med, 343, 938, 10.1056/NEJM200009283431307 Cristiano, 2009, Prevalence of multiple sclerosis in Buenos Aires: Argentina using the capture-recapture method, Eur J Neurol, 16, 183, 10.1111/j.1468-1331.2008.02375.x Lublin, 2003, Effect of relapses on development of residual deficit in multiple sclerosis, Neurology, 61, 1528, 10.1212/01.WNL.0000096175.39831.21 Weinshenker, 1989, The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability, Brain, 112, 133, 10.1093/brain/112.1.133 1998, Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group, Lancet, 352, 1498, 10.1016/S0140-6736(98)03334-0 1993, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter: randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group, Neurology, 43, 655, 10.1212/WNL.43.4.655 Jacobs, 1996, Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG), Ann Neurol, 39, 285, 10.1002/ana.410390304 Johnson, 1995, Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group, Neurology, 45, 1268, 10.1212/WNL.45.7.1268 Goodin, 2002, Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines, Neurology, 58, 169, 10.1212/WNL.58.2.169 Patti, 2010, Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence, Patient Prefer Adherence, 4, 1, 10.2147/PPA.S8230 Rice, 2001, Interferon in relapsing-remitting multiple sclerosis, Cochrane Database Syst Rev, CD002002 Putzki, 2010, Effects of natalizumab on circulating B cells: T regulatory cells and natural killer cells, Eur Neurol, 63, 311, 10.1159/000302687 Buttmann, 2010, Treating multiple sclerosis with monoclonal antibodies: a 2010 update, Expert Rev Neurother, 10, 791, 10.1586/ern.10.38 Niino, 2010, Update on the treatment options for multiple sclerosis, Expert Rev Clin Immunol, 6, 77, 10.1586/eci.09.75 Suzuki, 1996, A new immunosuppressant: FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes, Immunology, 89, 518, 10.1046/j.1365-2567.1996.d01-777.x Payne, 2007, The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors, Blood, 109, 1077, 10.1182/blood-2006-03-011437 Bandhuvula, 2005, The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity, J Biol Chem, 280, 33697, 10.1074/jbc.C500294200 Albert, 2005, Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification: chemical proof, and biological characterization of the biologically active species and its enantiomer, J Med Chem, 48, 5373, 10.1021/jm050242f Pinschewer, 2000, FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction: expansion, and memory, J Immunol, 164, 5761, 10.4049/jimmunol.164.11.5761 Brinkmann, 2000, FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation, Trends Pharmacol Sci, 21, 49, 10.1016/S0165-6147(99)01419-4 Mandala, 2002, Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists, Science, 296, 346, 10.1126/science.1070238 Brinkmann, 2002, The immune modulator FTY720 targets sphingosine 1-phosphate receptors, J Biol Chem, 277, 21453, 10.1074/jbc.C200176200 Brinkmann, 2007, Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology, Pharmacol Ther, 115, 84, 10.1016/j.pharmthera.2007.04.006 Mutoh, 2008, Lysophospholipid activation of G protein-coupled receptors, Subcell Biochem, 49, 269, 10.1007/978-1-4020-8831-5_10 Igarashi, 2009, Sphingosine-1-phosphate and modulation of vascular tone, Cardiovasc Res, 82, 212, 10.1093/cvr/cvp064 Allende, 2004, Expression of the sphingosine 1-phosphate receptor: S1P1, on T-cells controls thymic emigration, J Biol Chem, 279, 15396, 10.1074/jbc.M314291200 Pham, 2008, S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress, Immunity, 28, 122, 10.1016/j.immuni.2007.11.017 Pham, 2010, Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning, J Exp Med, 207, 17, 10.1084/jem.20091619 Metzler, 2008, Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure, Int Immunol, 20, 633, 10.1093/intimm/dxn023 Wehrli, 2001, Changing responsiveness to chemokines allows medullary plasmablasts to leave lymph nodes, Eur J Immunol, 31, 609, 10.1002/1521-4141(200102)31:2<609::AID-IMMU609>3.0.CO;2-9 Thangada, 2010, Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics, J Exp Med, 207, 1475, 10.1084/jem.20091343 Sallusto, 2004, Central memory and effector memory T cell subsets: function, generation, and maintenance, Annu Rev Immunol, 22, 745, 10.1146/annurev.immunol.22.012703.104702 Lanzavecchia, 2000, Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells, Science, 290, 92, 10.1126/science.290.5489.92 Sallusto, 1999, Two subsets of memory T lymphocytes with distinct homing potentials and effector functions, Nature, 401, 708, 10.1038/44385 Balatoni, 2007, FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis, Brain Res Bull, 74, 307, 10.1016/j.brainresbull.2007.06.023 Webb, 2004, Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice, J Neuroimmunol, 153, 108, 10.1016/j.jneuroim.2004.04.015 Kataoka, 2005, FTY720: sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration, Cell Mol Immunol, 2, 439 Kappos, 2010, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, N Engl J Med, 362, 387, 10.1056/NEJMoa0909494 Cohen, 2010, Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N Engl J Med, 362, 402, 10.1056/NEJMoa0907839 Lindsey, 2012, Sudden unexpected death on fingolimod, Mult Scler, 18, 257, 10.1177/1352458512438456 Warnke, 2011, Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis, Neuropsychiatr Dis Treat, 7, 519